According to the American Diabetes Association (ADA) and Kidney Disease Improving Global Outcomes (KDIGO) guidelines, SGLT2 inhibitors are now recommended first-line agents for patients with type 2 diabetes, CKD, and eGFR ≥20 mL/min/1.73 m2 with urinary albumin >200 mg/g creatinine (Grade A recommendation) (38, 39). Here, SLC5A2 is linked to chronic kidney disease.